Imaavy Treatment Associated With Sustained Functional and Strength Gains for 2 Years in Adolescents With gMG

Two-year findings from the phase 2/3 Vibrance-MG study (NCT05265273) showed sustained improvements in measures of daily function and muscle strength among adolescents with generalized myasthenia gravis (gMG) treated with Imaavy (nipocalimab-aahu; Johnson & Johnson, Spring House, PA). The ongoing open-label study enrolled 7 participants aged 12 to 17 years with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody–positive gMG and an insufficient response to stable standard therapy.

Two-Year Efficacy and Steroid-Sparing Outcomes

• Among participants with available data at week 108, mean Myasthenia Gravis Activities of Daily Living (MG-ADL) scores decreased 2.88 points from baseline.
• Mean Quantitative Myasthenia Gravis (QMG) scores decreased 8.25 points from baseline at week 108.
• Of 6 participants using corticosteroids at study entry, 3 reduced their dose and 1 discontinued treatment by 2 years.
• No new safety signals were reported, and the safety profile in adolescents was similar to that previously observed in adults.

Practical Implications in the Clinic

The findings provide longer-term data on functional outcomes, muscle strength, and corticosteroid use with Imaavy in adolescents with anti-AChR antibody–positive gMG. Interpretation is limited by the small, open-label cohort of 7 participants.

Source

Johnson & Johnson. Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with Imaavy (nipocalimab-aahu) in generalized myasthenia gravis (gMG). Published September 29, 2026. Accessed October 15, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-data-reinforcing-sustained-disease-control-and-improved-daily-function-achieved-with-imaavy-nipocalimab-aahu-in-generalized-myasthenia-gravis-gmg